ArticleACS pharmacology & translational science2026
Proteolysis Targeting Chimera (PROTAC) Linkerology Enhances the CDK-Degradation Selectivity Profile of a Multi-CDK Inhibitor: Discovery of Potent, Anti-Leukemic CDK9 Degraders.
Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The degradation efficiency of a PROTACbivalent compounds that link together a ligand for a protein of interest with a ligand for an E3 ligaseis governed, in part, by the length and flexibility of its linker ("linkerology"), as well as the accessibility of ubiquitinatable surface lysines. Based on the prior serendipitous discovery of the cyclin-dependent kinase 9 (CDK9)-selective PROTAC degrader "THAL-SNS-032", developed from the multi-CDK2/CDK7/CDK9 inhibitor SNS-032, we speculated that other multi-CDK inhibitors might likewise be transformed into CDK9-selective PROTACs, establishing a "linkerology" platform approach to enhancing CDK family member specificity (and beyond). We tested this hypothesis using AT7519, a multi-CDK2/CDK5/CDK9 inhibitor, and employing cereblon as the targeted E3 ligase. Accordingly, we built candidate PROTACs by linking AT7519 to one of two thalidomide derivatives; those molecules in which AT7519 and the thalidomide derivative were coupled via rigid linkers caused greater degradation of the CDK9 protein than those with more flexible linkers. Western blotting of human acute myeloid leukemia (AML) cells treated with AMC-3-221, our most CDK9-selective PROTAC, resulted in almost-complete reduction of the CDK9 protein, with no detectable degradation of CDK1, CDK2, or CDK5, and minimal degradation of CDK4 and CDK6, corroborated by global proteomics analysis. Subtle shortening or lengthening of AMC-3-221's rigid linker altered the CDK degradation selectivity profile, suggesting that continued linker variation may further enhance selectivity. Molecular modeling provided insight into the observed selectivity through the analyses of ternary complex stabilities. AMC-3-221 treatment rapidly decreased RNA and protein levels of oncogenic downstream targets of CDK9MCL-1 and c-/N-MYCand potently inhibited human AML and other types of human cancer cell lines, with less inhibition of a non-transformed cell line, via an on-target mechanism of apoptosis. AMC-3-221's CDK9 degradation potency (DC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.